Advertisement
The leader in healthcare business news, research & data

Pharmaceuticals

Akorn receives warning letter from FDA

Akorn receives warning letter from FDA

The Food and Drug Administration found an Akorn facility violated current good manufacturing practice regulations. The drugmaker's stock has taken a hit due to the warning letter.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print